Q Generation of target cell lines from subject fibroblasts and B-LCL -TASK NEARLY COMPLETE
To date, we have established fibroblast lines and EBV-transformed B cell lines in the context of other funded clinical studies in 20 HLA-A2 expressing patients with prostate cancer. These cell lines will be used as stimulator and target cell lines for experiments related to those proposed. A retroviral construct (pLNCX) containing the cDNA for human PAP has been used to transform these cell lines to express PAP. As described below, these lines will be used as target cells for cytotoxicity testing of peptide-specific lines only.
A2 expressing patients. After multiple in vitro stimulations I was unable to detect reproducible peptide-specific CTL activity as determined by chromium release assay using peptide-loaded target cells. This approach was therefore abandoned. However, PBMC from 20 HLA-A2 expressing individuals and 10 HLA-A2 expressing males without prostate cancer were used to evaluate peptide-specific responses with these 11 peptides as defined by IFNy release in response to peptide stimulation in an ELISPOT assay. This method identified 3 peptides for which both patients and controls had high peptide-specific T cell frequencies, implicating these as MHC class I epitopes. These were peptides found to have moderate-high specificity for HLA-A2 by in vitro T2 assays, and had not been previously identified as PAP epitopes. This work received a 2001 AFLCAC Scholar in Training Award and was presented in a poster at the 2001 national meeting of the American Association for Cancer Research. Work is ongoing to culture T cell lines on these specific peptides using PBMC from patients with the highest T cell frequencies as identified by ELISPOT, to confirm that peptide-specific T cells exhibit cytolytic activity. At that point, these results will be reported as a manuscript. In addition, the target cells generated from the task above from autologous systems and engineered to express PAP will be used to confirm that T cell lines exhibit cytolytic activity against autologous cells expressing PAP. While this is not the work initially proposed, this has turned out to be a more exciting and fruitful avenue of investigation.
Define HLA-A2 epitopes able to generate PAP-specific CTL using HLA-A2 transgenic mouse model in vivo system -TASK COMPLETE As described in the previous annual report, pilot experiments revealed that simple immunization with a boost 2 weeks later were not sufficient to initiate a peptide-specific T cell response. Other pilot experiments using well-characterized HLA-A2 binding peptides (influenza matrix peptide, EBV 9-mer HLA-A2 epitope) with and without helper T cell epitopes likewise gave poor and inconsistent results. This approach was therefore abandoned, particularly since direct assay of PBMC from patients with prostate cancer (as described above) identified HLA-A2 epitopes directly, without the need for an animal model.
Determine whether T cell lines and clones specific for PAP-derived CTL peptides can lyse autologous cells expressing PAP and/or HLA-matched prostate tumor cell lines -TASK COMPLETE -RELATED EXPERIMENTS ONGOING In pilot assays, all 11 peptides were used as stimulator antigens to attempt to generate peptidespecific T cell lines in ten HLA-A2 expressing patients. After multiple in vitro stimulations I was unable to detect reproducible peptide-specific CTL activity as determined by chromium release assay using peptide-loaded target cells, let alone autologous targets expressing PAP or prostate tumor cell lines. This approach, therefore, was abandoned as not feasible. However, as described above, related work is ongoing following the identification of 3 specific HLA-A2 epitopes for PAP found by the ELISPOT. In this work, T cell lines are being cultured on specific peptides using PBMC from patients with the highest T cell frequencies identified by ELISPOT. These lines will then by tested for cytolytic activity using peptide-pulsed HLA-A2 expressing target cells, autologous cells expressing PAP, and the LNCaP HLA-A2-expressing prostate cancer cell line. a Informatics -NONE □ Funding applied for based on work supported by this award: An application for a National Institutes of Health K23 (Mentored physician scientist award) is pending, the aims of which follow directly from the research funded by this DOD Award. The aims proposed in the new proposal are to 1) identify the lymphocyte populations responsible for eliciting and maintaining prostatitis in a rat model using a DNA-based vaccine targeting PAP; 2) identify serologic antigens in patients with prostatitis that are recognized in patients with prostate cancer; and 3) determine if PAP-specific CD8+ T cells can be elicited in patients with prostate cancer by means of a DNA-based vaccine in the context of a clinical trial.
a Employment or research opportunities applied for: I accepted a position as Assistant Professor of Medicine within the Experimental Therapeutics group of the Section of Medical Oncology in the Department of Medicine at the University of Several prostate cancer antigens are under clinical investigation as potential targets for immune based treatments of prostate cancer, including prostate specific antigen (PSA) 1 -2 and prostatic acid phosphatase (PAP). 3 Despite the fact that clinical prostate cancer vaccine trials are under way, little is known about the inherent immunogenicity of prostate cancer. In fact, it has been suggested that the prostate gland is immunologically favored, given the purported immunosuppressive characteristics of the seminal fluid 4 and the supposed absence of a lymphatic system within the prostate. 5 Moreover, research performed nearly 20 years ago suggests that cell mediated immune responses are depressed in patients with prostate cancer, as judged by lymphocyte proliferation in response to mitogens, delayed type of hypersensitivity skin testing to dinitrochlorobenzene and T cell aggregation studies. 6 -7 Later studies implicate the loss of MHC class I expression as a mechanism of immune escape by prostate cancer cells. 8, 9 Within the last 20 years several proteins have been idenAccepted for publication May 11, 2000 . * Supported by Grant P32 CA09515-14 from the National Institutes of Health, Washington, D. C. and the Berlex Oncology Foundation.
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t Recipient of National Institute of Diabetes and Digestive and Kidney Disease OBRIEN Center Award. tified whose expression is essentially limited to the prostate, including PSA and PAP, and several other proteins have been identified likely involved in the metastatic progression of prostate cancer. Unlike melanoma, however, in which tumor antigens have been identified based on their inherent immunogenicity, 10 " 12 to our knowledge there have been no reports on the immunogenicity of these prostate cancer associated proteins.
We address the question of the inherent immunogenicity of prostate cancer by looking at antibody immunity to PSA, PAP, p53 and HER-2/neu, which are prostate cancer associated proteins that are known tumor antigens. PSA and PAP were chosen as the 2 best characterized prostate specific proteins. There has been a report of a probable humoral immune response to PSA occurring in patients with metastatic prostate cancer, 13 and others have demonstrated that it is possible to culture human cytotoxic T lymphocytes in vitro specific for PSA 14, 15 and PAP, 16 suggesting that tolerance to these proteins might be circumvented in vivo. p53 and HER-2/neu were chosen as biologically relevant proteins, each implicated in the metastatic progression of prostate cancer and each previously shown to be tumor antigens in breast cancer. 17 ' 18 In our study we detected an antibody response to 1 or more of these 4 proteins in 37% (74 of 200) of patients compared with 16% (16 of 100) of male controls. Antibody responses to PAP (5.5%, 11 of 200) and p53 (6%, 12 of 200) were not 1825 "significantly different from the control populations but antibody responses to PSA (11%, 22 of 200) and HER-2/neu (15.5%, 31 of 200) were significantly different from the control populations (p = 0.02 and p = 0.0004, respectively). Higher titer responses were most prevalent in patients with androgen independent prostate cancer, although this did not reach statistical significance for PSA. These findings indicate that prostate cancer is an immunogenic tumor, and that even patients with advanced stage prostate cancer can mount an antibody immune response to proteins expressed by the tumor.
METHODS
Patient populations. With informed consent, sera were obtained from 200 patients with prostate cancer at the University of Washington Medical Center between 1997 and 1999. Sera were grouped according to disease stage and treatment status. Pretreatment sera were drawn within 1 week of surgery from 48 patients undergoing radical prostatectomy (group 1). Group 2 consisted of 55 patients with stage B or C tumors, who had been treated with radical prostatectomy or brachytherapy and had no evidence of disease recurrence. These sera were collected at a variety of times following surgery. Group 3 included 41 patients with stage D prostate cancer, on androgen ablative therapy and with evidence of androgen responsive disease by PSA monitoring. Group 4 consisted of 56 patients with metastatic, androgen independent prostate cancer. Sera in these latter 2 groups were drawn at different times in the treatment course of individual subjects. Control sera were obtained from male volunteer blood donors 37 to 73 years old, without histories of prostate or other cancers, who contributed blood products at the Puget Sound Blood Bank. All sera were stored in aliquots at -20C until used.
Detection of PAP and PSA specific antibody responses in patients with prostate cancer by enzyme-linked immunosorbent assay (ELISA). Antibodies recognizing PAP and PSA were detected by ELISA using highly purified proteins. We added 2 jLig./ml. purified protein in 50 mM. sodium carbonate buffer (pH 9.6) to experimental wells overnight at 4C. Plates were then blocked with phosphate buffered saline/1% bovine serum albumin for 1 hour at room temperature. After washing with phosphate buffered saline/0.1% Tween-20, plates were then probed with human sera at concentrations of 1:25, 1:50, 1:100 and 1:200 for 1 hour at room temperature, with serum added to experimental and blank wells. Serum from a patient with previously documented antibodies to PAP and PSA was included on each plate as a positive control and to serve as an interplate control. After a 1-hour incubation plates were again washed and a peroxidase-conjugated sheep anti-human Ig antibody diluted 1:5,000 in phosphate buffered saline/1% bovine serum albumin was added. Following a 45-minute incubation at room temperature, the plates were washed and developed with tetramethylbenzidine peroxidase substrate according to manufacturer instructions.
Reactions were monitored at optical density of 650 nm. and stopped with addition of hydrochloric acid to 0.5 N. concentration when the optical density of the positive control sera reached 0.3. The plates were then read at optical density of 450 nm. and the change in optical density was determined as the difference between the optical density of experimental and blank wells. Titers were calculated using a cutoff value determined from the mean + 2 standard deviations (SD) of the control population change in optical density values at the most concentrated sera dilution used (1:25) . The change in optical density of the positive control sera varied by less than 1 SD among plates, and titered at 1:200 for PSA and 1:400 for PAP. All titers greater than 1:50 were confirmed in an independent assay.
Detection ofp53 specific antibody responses in patients with prostate cancer by ELISA. Antibodies recognizing nonmutated p53 were detected using a capture ELISA method, similar to that previously reported. 19 Briefly, 96-well ELISA plates were incubated overnight at 4C with a mouse monoclonal antibody specific for human p53 in 50 mM. sodium carbonate buffer (pH 9.6). Plates were then blocked as described previously, and a lysate from a p53 abundant human breast cancer cell line, BT20, was added to experimental wells as a source of antigen. After incubation, plates were then washed, probed with human sera at concentrations of 1:25, 1:50, 1:100 and 1:200, and developed as described previously. Serum from a single patient with previously documented antibodies to p53 was included on each plate as a positive, interplate control. Titers were calculated as described previously.
Detection of HER-21' neu-specific antibody responses in patients with prostate cancer by ELISA. Capture ELISA was performed as previously reported, 18 using an IgG specific secondary antibody. As for the other ELISA assays, serum from a single patient with a previously documented IgG antibody response to HER-2/neu was included on each plate as a positive control and to serve as an interplate control. 18 Likewise, all titers greater than 1:50 were confirmed in an independent assay. Previous studies have shown that antibody responses with titers 1:100 or greater are not found in noncancer control sera. 18 Statistical comparison of study populations was performed using a chi-square test, with p £0.05 considered statistically significant.
RESULTS
Antibody immunity to PSA can be detected in the serum of patients with prostate cancer. Sera from 200 patients with various stages of prostate cancer and from 100 volunteer male control blood donors were screened for the presence of antibodies to PSA as described ( fig. 1 ). Detectable titers (1:50 or greater) were found in 22 (11%) of 200 patients, which was statistically different from the control population (3%, 3 of 100, p = 0.02). The difference between patients and controls was more striking at titers 1:100 or greater, as 6.5% (13 of 200) of patients had detectable antibodies compared with none of the controls (0 of 100, p = 0.009). Analysis by stage of disease also suggested that antibody responses were most common in patients with androgen independent disease (6 of 56 with titers 1:100 or greater, 10.7%). However, this sub- fig. 3) , which was not different from the control population (4 of 100, 4%, p = 0.57). No differences were noted with respect to stage of disease. Of interest, however, the patient with the highest antibody titer to PAP also had detectable antibodies to PSA.
Patients with prostate cancer have antibodies top53. Of the 200 patients 12 (6%) and of the 100 controls 7 (7%) had low titer antibody immunity to p53 ( fig. 4) , which was not statistically different (p = 0.74). No differences were noted with respect to disease stage.
Antibody immunity to HER-2/neu can be detected in the serum of patients with prostate cancer and is most prevalent in patients with androgen independent disease. Sera from the 200 patients with prostate cancer were screened for antibodies to HER-2/neu using the titer based assay described previously, 18 and the results were compared with 100 controls. Overall, 31 (15.5%) of 200 patients had detectable antibodies to HER-2/neu compared with 2 (2%) of 100 controls (p = 0.0004) at titers 1:50 or greater ( fig. 5 ). At titers 1:100 or greater, at which it has previously been reported that antibody responses are not detected in patients without cancer, 18 8.5% (17 of 200) of the patient population had detectable antibodies (p = 0.003). At this titer HER-2/neu-specific antibody responses were most prevalent in patients with androgen independent disease (9 of 56, 16%) compared with the other combined subgroups of patients (8 of 144, 5.6%, p = 0.02). As indicated previously, 1 patient with advanced stage disease and antibodies to HER-2/neu also had detectable antibodies to PSA. cer. Unlike melanoma, however, in which tumor associated antigens have been defined based on the endogenous immune response to particular proteins, 11 -20 there has been little investigation of the immunogenicity of prostate cancer associated proteins. We report an overview of the humoral immunogenicity of 4 prostate cancer associated proteins, 2 of which are essentially prostate specific, and 2 of which are biologically relevant to the progression of prostate cancer and have been shown to elicit immune responses in patients with other tumors. The specific questions we addressed were 1) do patients with prostate cancer have antibody immunity to known prostate cancer associated antigens, 2) what is the prevalence of this immunity and 3) is immunity to individual proteins associated with the stage of disease.
Patients with prostate cancer can have antibody immunity to prostate cancer associated proteins. While there were no cancer specific humoral responses detected to PAP or p53, antibody responses to PSA and HER-2/neu were significantly different from a control population. It is unclear why there would be more antibody responses detected to PSA than PAP, given that they are both prostate specific proteins. This find- ing may be a reflection of expression levels of these proteins, with typically higher serum levels of PSA than PAP detected in patients with metastatic disease, and consequently perhaps greater uptake and antigen presentation. On the other hand, this finding may reflect the inherent humoral immunogenicity of these specific proteins, with perhaps higher tolerance to PAP, which may share epitopes with other tissue phosphatases than PSA. In any case the antibody responses detected were generally low titer, although a few patients had high titer antibodies to PSA or HER-2/neu. The presence of antigen specific immunity detected only in patients with cancer suggests that it is the presence of tumor itself that elicits an immune response. Moreover, the fact that the responses to HER-2/neu were IgG indicates the likely presence of antigen specific CD4+ T cell responses mediating immunoglobulin class switch and participating in this immune response.
There was a high prevalence of humoral immune responses to the proteins tested in patients with prostate cancer at titers 1:50 or greater. Of the 200 patients 26% had detectable antibodies to PSA and/or HER-2/neu compared to only 5% of the control population. The prevalence of HER-2/neu-specific antibodies with titers 1:100 or greater, particularly in patients with androgen independent prostate cancer (16%), was similar to what has previously been reported in other adenocarcinomas, such as early stage breast cancer (11%) 18 and colorectal carcinoma (14%). 21 In contrast, autoantibodies to p53 have been detected in 24% to 30% of patients with ovarian, breast and lung cancers. 17 -19 -22 Our results are consistent with studies by Lang et al, who reported a low incidence (3%) of p53 autoantibodies in prostate adenocarcinomas compared with other urogenital tumors. 23 This low prevalence of p53 autoantibodies may be a result of less homogeneous, nuclear accumulation of p53 in prostate cancer compared with other adenocarcinomas. 24 In general, we found that the majority of humoral immune responses occurred in patients with androgen independent prostate cancer. The observation that the majority of responses were in patients with late stage disease may reflect that these low level immune responses occur as a result of shed antigens in more bulky disease. Despite the mechanism, however, this observation suggests that even patients with metastatic disease are able to mount an immune response to the tumor.
Tumor antigen specific cytotoxic T lymphocytes have long been considered critical final effectors in an effective antitumor immune response. 25 Others and we have found in a rodent model that a PAP specific Thl phenotype with PAP specific cytotoxic T lymphocytes is critical for actual destruction of prostate tissue. 26 Abstract. Prostate cancer is a significant health problem and one of the leading causes of cancer-related death among men. Given the typically long natural history of the disease, there is considerable interest in developing new therapies to treat or prevent metastatic disease, and cancer vaccines are a particularly attractive immune-based approach. Early clinical studies using non-specific immunomodulatory treatments have met with limited success, but also suggest that improved immunologic approaches might be useful in treating human prostate cancer. Over the last decade, the identification of immune cells responsible for actual destruction of prostate tissue and advances in immunologic and molecular techniques have led to a variety of vaccination approaches that are currently being evaluated in human clinical trials. The present article discusses the rationale in animal models for particular immunization strategies and describes the vaccines currendy being used in patients with prostate cancer. The ongoing identification of tumor antigens and proteins involved in prostate cancer progression and the development of better immunologic animal models suggest a hopeful future for the design of effective prostate cancer vaccines.
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Prostate cancer is a significant health problem worldwide and currently second only to skin cancer as the most diagnosed male malignancy in the United States 3 . After appropriate local therapy, approximately 30% of patients will develop metastatic disease and approximately 10% of patients will die of their disease. At present there is no cure for metastatic prostate cancer and no accepted adjuvant therapy proven to reduce tumor progression. There is considerable interest in developing new therapies to treat or prevent metastatic disease. Recently, gene therapy and various immune-based strategies have been explored as possible treatments for prostate cancer 21, 23, 24 . Given the generally long natural history of prostate cancer, tumor vaccines are a particularly attractive immune-based approach to consider for adjuvant therapy.
Background
Initial investigations performed nearly 20 years ago suggested prostate cancer is not an immunogenic tumor. Early reports suggested the prostate gland is devoid of afferent lymphatics 52 . In addition, non-specific tests of immune function, such as T cell rosette formation, T cell blastogenic response to mitogen Abbreviations used: TTL -tumor-infiltrating lymphocytes, DTH -delayed type hypersensitivity, PSA -prostate specific antigen, GM-CSF -granulocyte-macrophage colony stimulating factor, PAP -prostatic acid phosphatase, PSMA -prostate specific membrane antigen, CTL -cytotoxic T lymphocytes, MHC -major histocompatibility complex, KLH -keyhole limpet hemocyanin. 36 . Other studies documented the reduction of major histocompatibility complex (MHC) class I molecules in metastatic prostate cancer lesions and disruption of the prostatic acid phosphatase TAP transporter machinery in human prostate cancer cell lines, suggesting possible mechanisms of escape from immune detection 46 . Finally, the absence of prostate tumors occurring in T cell deficient mice suggested that the presence of prostate cancer was not due to a defect in immune surveillance 43 . Such findings led investigators to conclude that prostate cancer is not an immunogenic tumor .
More recent studies have challenged these assumptions. First, several reports have confirmed the presence of lymphocytic infiltrates in the prostate, suggesting the prostate is not immunologic.ally privileged 34 . Second, reported cases of granulomatous prostatitis demonstrate that inflammatory reactions occur within the prostate gland 28 . Third, prostatic apoptosis associated with androgen ablative therapy has been shown to be, in part, mediated by an immune response in a rat model 30 . Fourth, the presence of tumor-infiltrating lymphocytes (TEL) in prostate cancer specimens has been associated with higher 10-year survival than the absence of TIL, suggesting cancer-specific immune responses may play a role in tumor surveillance 59 . Moreover, our group has demonstrated that patients with prostate cancer develop humoral immunity to prostate specific antigen (PSA) and HER-2/neu, and the prevalence of these immune responses is more common in patients with metastatic disease (MCNEEL, submitted). Finally, we have also shown that patients with prostate cancer have preexistent T cell responses to PSA and PAP of a Thl-like phenotype, suggesting that potentially therapeutic immune responses already exist in vivo, albeit at low levels (MCNEEL, submitted).
Recent advances in molecular biology and basic immunology, including the identification of cytokines responsible for promoting specific types of immune responses, an identification of the immune cell subsets responsible for eradicating tumor cells, and the development of appropriate animal tumor models, have led to a variety of new approaches to generate tumor-specific immune responses by means of tumor vaccines. The present article will discuss the rationale in animal models for particular immunization strategies and describe the immunization strategies currently being used in patients with prostate cancer. These animal models and the human vaccine trials discussed are summarized in Table 1 .
Whole Cell Vaccines
The goal of whole cell vaccines is to generate an anti-tumor immune response to a wide variety of tumor-associated antigens. Traditionally, the major difficulty with this approach has been that whole cell vaccines are typically only weakly immunogenic. Early studies in human vaccines with irradiated prostate cancer cells as vaccines showed modest evidence of an immunologic response when administered with foreign proteins 5, 42 . These findings led researchers to attempt to increase the immunogenicity of cellular vaccines themselves. The Dunning rat model provided a good model for study, as the MatLyLu derived cell line forms anaplastic, androgen-independent tumors that spontaneously metastasizes to the lymph nodes and lung when injected orthotopically in rats 25 . Studies showed that this tumor was poorly immunogenic; splenocytes from tumor-bearing animals demonstrated no cytolytic activity in vitro to MatLyLu cells and immunization of animals with irradiated MatLyLu cells generated no protection from subsequent exposure to live tumor cells 60 . Studies conducted attempted to increase the immunogenicity of such cellular vaccines by transfecting them with immunomodulatory cytokines, similar to previous studies in animal models of melanoma 11 -l6 . Dunning rat prostate cancer cell lines, when transfected to express EL-2 and to a lesser extent granulocyte-macrophage colony stimulating factor (GM-CSF), and then used to immunize rats, protected immunized animals from subsequent challenge with live tumor cells 60 . Splenocytes from immunized animals showed cytolytic activity toward non-transfected MayLyLu cells 60 . Similar results were found by SANDA et al. 45 with GM-CSF transfected tumor vaccines in the Dunning rat model. This group went on to demonstrate that primary human prostate cancer cells could be transfected to express human GM-CSF 45 . These findings were ultimately translated to human clinical trials in renal cell carcinoma 48 , melanoma 53 , and the first report of a GM-CSFmodified autologous prostate cancer cell vaccine trial has recently been reported by SIMONS et al. 49 . In this study, 8 patients with large primary tumors undergoing radical prostatectomy had primary tumor lines established from specimens obtained at surgery. These lines were then transfected to express human GM-CSF, irradiated, and used to immunize patients 3 times over 3-week intervals. Eight of 11 patients were able to complete the vaccination series, 6 of whom had evidence of progressive disease, and 2 had transient clinical responses as determined by PSA serum levels. Three of the patients developed antibody responses to proteins expressed by 49 . Of note, 2 of 8 patients had delayed type hypersensitivity (DTH) responses to autologous tumor cells prior to vaccine treatment, suggesting that patients develop either low-level or nontherapeutic immune responses to their tumors in vivo.
The whole cell vaccine approach has potential advantages as well as disadvantages. Given that appropriate tumor antigens have not really been identified for prostate cancer as they have for other human solid tumors, one potential advantage is that individual antigens are not necessarily targeted. The goal of cellular vaccine approaches is to generate an immune response against the most immunogenic proteins. On the other hand, this also represents a disadvantage, as immunizing with whole cells exposes the immune system to hundreds and perhaps thousands of irrelevant proteins, possibly swamping out a potentially therapeutic immune response. In addition, the transfected cytokine itself may be immunogenic. Our group has demonstrated that immune responses to recombinant human GM-CSF can develop after vaccination 36 . Moreover, whole cell vaccines are laborious, costly, and of necessity tailor-made for individual patients. Such vaccine strategies may not be feasible for large-scale studies. Likewise, similar to vaccines used for the prevention of infectious diseases, the role of prostate cancer vaccines, and tumor vaccines in general, will likely be in the adjuvant setting with minimal detectable disease S5 . In the study reported by SIMONS et äl. 49 , the authors note that the production of transfected tumor vaccines necessitated large primary tumors, and therefore vaccinations were restricted to patients with large, high-risk tumors. For this reason, their approach in phase LI studies, and the approach of others using similar cytokine-transfected prostate cancer cellular vaccines, is to use cytokine-transfected allogeneic prostate cancer cell lines 49 .
Dendritic Cell Vaccines
Dendritic cells are potent antigen presenting cells 54 . Investigations in murine models have shown that dendritic cells pulsed ex vivo with lysates from tumor cells can be used to vaccinate naive syngeneic mice, protecting animals from tumor challenge and reducing the number of metastases 6, l2 . These studies have demonstrated that a tumor-specific immune response can be generated by dendritic cell immunization, and have led to the initiation of human clinical trials in prostate cancer. G. Murphy and colleagues initially reported that autologous dendritic cells from patients with prostate cancer could be pulsed ex vivo with either autologous tumor cell lysates or an HLA-A2-restricted peptide epitope from prostate specific membrane antigen (PSMA) to generate tumor-specific or peptide-specific cytotoxic T lymphocytes (CTL) in vitro 58 . This group then went on to pioneer the use of dendritic cell vaccines for prostate cancer in an antigen-specific fashion using two putative HLA-A2-restricted MHC class I epitopes from the PSMA protein. To date, these investigators have observed some potential clinical responses in select patients, and perhaps some evidence of PSMA-specific cellular immune responses elicited by vaccinations 39, 44 . In principle, using the antigen presenting cells that most directly promote cellular immune responses is a very reasonable approach. As an example, DHODAP-KAR et al. 7 demonstrated that healthy subjects could be effectively immunized, as assessed clinically by DTH testing and by quantitative in vitro assays of antigen--specific T cells, with autologous dendritic cells pulsed with 1 of 3 well-characterized immunogenic proteins or peptide epitopes in a single immunization. Animal studies using dendritic cells pulsed with tumor cell extracts have demonstrated that knowledge of the specific antigens recognized need not be known, as animals immunized in this fashion develop an anti-tumor immune response 12 . Like whole cell vaccines, however, the generation of dendritic cells is a labor-intensive, individualized therapy that may be difficult to extrapolate to larger pools of patients. Nonetheless, this strategy is entering phase II/III studies for the treatment of advanced melanoma, and shows promise for future development of prostate cancer vaccines.
Antigen-Specific Vaccines
Given the disadvantages and individualized therapy inherent in cellular vaccines, several investigators have focused on antigen-specific vaccines. The theoretical advantages of targeting a specific antigen include the ability to concentrate the immune response against one specific, immunogenic target and thereby avoid exposure to extraneous or potentially disadvantageous antigens. Certainly in the case of vaccines for infectious diseases, an immune response directed against single, immunogenic proteins may be advantageous 31, 40 . In addition, this approach does not generally rely on culturing cells from individual patients, and therefore may be more amenable to treating larger numbers of patients in a reproducible fashion. Finally, the identification of proteins specifically involved in the metastatic progression of prostate cancer may permit vaccines to interfere directly with the progression of the disease. The identification of several prostate-specific proteins over the last several years and the ongoing elucidation of the pathways involved in prostate cancer progression, metastasis, and androgen independence make antigen--specific vaccines an attractive strategy for the future development of prostate cancer vaccines.
Several delivery systems for antigen-specific vaccines are being investigated, including recombinant bacterial and viral delivery systems, recombinant proteins in adjuvant, MHC-binding peptide epitopes, the use of various cytokines as immunomodulatory adjuvants, and bacterial plasmid DNA encoding the target antigen. Each of these approaches will be discussed in the context of the specific antigens currently being targeted in human prostate clinical trials.
Prostatic Acid Phosphatase
The identification over the last 10 years of several proteins whose expression is essentially limited to the prostate has provided several candidate antigens for vaccine trials. PAP was first identified in 1938, and was initially used as a serum marker for the detection of prostate cancer 17, 20 . Given the early identification of a rat homolog, our group and others have used a rodent model to study vaccination strategies targeting this prostate-specific protein. FONG et al. 15 reported that immunizing rats with recombinant vaccinia virus engineered to express rat PAP was not effective in generating an immune response to PAP. By immunizing rats with vaccinia virus expressing the human homologue, however, rats generated a cross-reactive immune response with the generation of PAP-specific CTL and destruction of prostate tissue. In similar studies, we have found that immunizing rats with vaccinia-PAP constructs repeatedly does not generate a PAP-specific response, but immunizing first with vaccinia-PAP and then boost-ing with PAP protein in adjuvant leads to a Th.1 biased cellular response with the generation of destructive prostatitis 35 . The results of these studies have provided important information for the design of human prostate cancer vaccine strategies. First, an antigen-specific immune response is capable of destroying prostate tissue in vivo. Second, the effector cells are predominantly Thl-like with antigen-specific CTL; antigen-specific antibody responses did not result in destructive prostatitis. Thud, repeated immunizations with a viral vector do not necessarily lead to an antigen-specific immune response in the case where a "self protein is targeted most likely because of the overwhelming majority of foreign, more immunogenic proteins introduced by means of viral vaccination. FONG et al.
14 have used this information to initiate a clinical trial targeting PAP by using autologous dendritic cells pulsed ex vivo with the recently identified mouse PAP homolog. By this strategy, they preliminarily report that patients develop T cell responses to PAP.
Prostate Specific Antigen
The essentially prostate-specific expression of PSA has made it a natural target for antigen-specific vaccine strategies. We have demonstrated that patients with prostate cancer, and particularly the subgroup of patients with metastatic prostate cancer, develop both a humoral and cellular immune response to PSA 37 22 reported the construction of a recombinant vaccinia virus expressing human PSA and its safety and efficacy in non-human primates in generating a PSA-specific antibody response. These results have led to a phase I/II trial evaluating the safety and efficacy of a recombinant vaccinia-PSA (PROST-VAC) vaccine construct in patients with stage DO prostate cancer. SANDA et al. 47 have recently reported the results of this trial, in which 1 of 6 patients developed an IgG antibody response to PSA, and one patient had stable serum PSA levels following immunization. The investigators do not report whether patients generate T cell immune responses. Given the limited number of immunizations that can be performed with vaccinia virus due to the overwhelming immune response to the vector itself, investigators have initiated a phase II cooperative study using either recombinant fowlpox-PSA or fowlpox-PSA with vaccinia-PSA in a prime-boost strategy.
There are multiple reports in animal models that immunization strategies using bacterial plasmid DNA alone as the delivery system is a potent means of generating cellular immune responses, particularly CTL responses 57 . Advantages of DNA immunization are that it essentially removes exposure to other competing antigens expressed in viral immunization strategies and is not MHC-restricted as are peptide vaccination strategies. In an animal model, KIM et al. 29 have used plasmid DNA encoding human PSA under a eukaryotic expression promoter as a means of immunizing mice. This strategy was effective at generating both humoral and CTL responses specific for PSA. Human prostate cancer vaccine trials using DNA as the antigen delivery system are being contemplated.
One of the limitations to vaccine strategies targeting PSA is that serum PSA levels are increasingly becoming accepted as a surrogate clinical endpoint in prostate cancer treatment trials 2 . Monitoring PSA levels may not be a suitable clinical endpoint in vaccine trials in which immune responses are generated to this protein. Another limitation has been the absence of relevant animal models, since mice and rats do not have a PSA homologue. WEI et al. 61 have reported the development of a transgenic mouse model that expresses human PSA in a prostate-restricted fashion. This model, and similar transgenic animal models, will provide valuable systems to evaluate the safety and potential efficacy of different vaccine strategies targeting PSA and other antigens in a preclinical fashion.
Prostate Specific Membrane Antigen
PSMA was originally identified and cloned as the protein recognized by a monoclonal antibody raised against the human metastatic prostate cancer cell line LNCaP 27 . Ribonuclease protection studies demonstrated that expression of the protein is nearly restricted to the prostate, and malignant prostate tissue in general highly expresses the protein 26 . The presence of a membrane-bound, prostate-specific protein suggested it might be a good protein for diagnostic imaging studies to detect prostate cancer, as well as a target antigen for immunotherapeutic strategies. As described above, G. Murphy and colleagues reported that dendritic cells from prostate cancer patients could be pulsed ex vivo with an HLA-A2-restricted peptide epitope from PSMA to generate peptide-specific CTL 58 and are conducting several clinical trials using dendritic cells to generate immunity to PSMA.
Cancer-Associated Membrane Carbohydrates
Specific membrane-bound carbohydrate moieties, such as GM2, MUC1, globo H and Thompson-Friedenreich antigen, have been found to be expressed preferentially on the surface of a variety of different tumor cells, suggesting that they may be candidate targets for immunotherapeutic approaches 32 . Investigators at Memorial Sloan-Kettering Cancer Center screened primary and metastatic human prostate tissues compared with a panel of normal tissues by immunohistochemistry and identified several membrane-bound carbohydrate antigens that are overexpressed on malignant prostate tissue compared with normal tissues 63 . They went on to initiate a phase I vaccine trial in prostate cancer targeting the globo H hexasaccharide, a membrane-bound carbohydrate molecule 51 . In this study, patients were immunized subcutaneously monthly for 5 months with globo H hexasaccharide conjugated to the keyhole limpet hemocyanin (KLH) carrier antigen in an immunologic adjuvant, QS-21. A similar immunization strategy had been used previously in patients with melanoma targeting the GM2 ganglioside antigen, with evidence of IgG antibody responses being generated to GM2 with this approach 33 . In the globo H study, the investigators report IgM antibody responses to globo H and stable serum PSA slopes compared with pre-treatment PSA slopes in specific patients over a 2--year period, suggesting that such treatment may have a clinical effect. A new study targeting another carbohydrate antigen, the Thompson-Friedenreich antigen, conjugated to KLH in QS-21 adjuvant, is underway, but no results are yet available 50 .
antibody and T cell responses to HER-2/neu that are not detected in a control population 8 . These responses are low-level, but suggest that immune responses to HER-2/neu can be generated in vivo. Relevant animal models demonstrated that immunization of rats with either the human homologue or with MHC class Il-binding peptides derived from rat PAP are capable of eliciting rat new-specific T cell responses 10 . In a niu transgenic mouse model of human breast cancer, immunization of mice with MHC class Il-binding peptides with GM-CSF as an adjuvant is not only capable of eliciting anti-new protein-specific T cell responses, but in protecting immunized animals from developing tumors (unpublished data). These results have led to a human clinical trial targeting HER-2/neu using MHC class Il-binding peptides with GM-CSF as an adjuvant. In an interim summary, 8 of 8 patients developed peptide-specific T cell immunity to the immunizing peptides and 6 of 8 developed HER-2/neu-specific T cell immunity 9 . The role of HER-2/neu in prostate cancer progression has been unclear, with different groups reporting differing findings about the expression of HER-2/neu in primary prostate cancers 18, 41 . Recent data, however, suggests that HER-2/neu overexpression may permit androgen-independent growth of prostate cancer cells 4 . We have reported that patients with prostate cancer, and in particular the subgroup of patients with androgen-independent prostate cancer, have preexisting antibody immunity to HER-2/neu, similar to HER-2/neu-overexpressing breast cancer (MCNEEL, submitted). Given these findings, and based on our animal model data that a CTL response is critical for mediating destruction of prostate tissue, we have initiated a phase I vaccine trial using a well-characterized HLA-A2-restricted 9-mer MHC class I-binding epitope (p369) derived from the amino acid sequence of HER-2/neu 1, l \ In this trial, peptide is administered intradermally with either GM--CSF as a vaccine adjuvant, or in the course of flt3 ligand stimulated dendritic cell mobilization. Flt3 ligand is a potent growth and differentiation factor for dendritic cells, and consequently the purpose of the study is to evaluate whether dendritic cells expanded in vivo are capable of properly presenting peptide antigen to generate an antigen-specific CTL response.
HER-2/neu
HER-2/neu is well documented as a tumor-associated antigen in human breast, ovarian, and colon cancer 1, 8 11, 13, 16, 33, 34) .
PAP is a potential tumor-associated antigen in prostate cancer, given that expression of PAP is essentially restricted to prostate tissue (35, 36), including metastatic prostate cancer (37, 38). Studies (19) in rats have demonstrated that a CTL response directed at the rat PAP homologue will destroy prostate tissue in vivo. As noted above, investigators have identified, in a human in vitro system, several HLA-A2 peptide epitopes derived from human PAP. PAP peptidespecific CTLs can be cultured from the peripheral blood of volunteer male blood donors and are able to lyse an MHC-restricted prostate cancer cell line (27) . The use of CTL peptide epitopes in a human vaccine study to elicit PAP-specific CTLs has been contemplated (27). In the current study, we sought to identify PAP-specific Th peptide epitopes that might be used to elicit a PAP-specific Th response in the context of a peptide-based vaccine. We have identified previously (15) subjects with prostate cancer who have PAP-specific Th responses. Using PBMCs from subjects with and without PAPspecific Th responses, we screened a panel of 10 potential peptide epitopes for peptide-specific T-cell proliferation. Four peptides were identified for which peptide-specific T-cell proliferation occurred in the majority of patient PBMC samples that also exhibited PAPspecific T-cell proliferation. PBMCs from patients with prostate cancer and without PAP-specific T-cell responses were then cultured in vitro with each of these four peptides. Peptide-specific T-cell lines could be generated from two of the four peptides that also proliferated in response to PAP protein stimulation. The ability of these two peptides to elicit PAP-specific Th responses suggests that they represent naturally processed PAP-specific MHC class II epitopes. There-5161 fore, these peptides are reasonable candidates for consideration for inclusion in peptide-based vaccines designed to elicit PAP-specific CD4+ T-cell responses. Peptides. The amino acid sequence of human prostatic acid phosphatase was scanned using the software analysis package Tsites (39). On the basis of this analysis, 10 15-18-mer oligopeptides derived from the amino acid sequence of PAP were synthesized and purified to >80% by high-performance liquid chromatography, and the identity and purity was confirmed by mass spectrum analysis (United Biochemical Research, Inc., Seattle, WA). Purified peptides were reconstituted in sterile water, filtered, and stored in aliquots at -20°C. Peptide sequences are shown in Table 1 . Table  1 . Unlike MHC class I molecules, which typically bind peptides of 9 to 10 amino acids in length, MHC class n molecules are generally believed to be more permissive in the length and exact amino acid sequence of bound peptide (47) . In studies defining the Th epitopes of tetanus toxoid, panels of overlapping peptides were screened for their ability to stimulate T-cell proliferation in PBMCs from tetanusimmune subjects. Peptides of greater than 12 amino acids and less than 31 amino acids and typically in the range of 14 to 16 amino acids were found to be most efficient in defining recognized epitopes (48). For that reason, 15 to 18 amino-acid peptides were constructed for the current study.
MATERIALS AND METHODS

Subjects
Evaluation of Potential Immnnogenic Epitopes by T-cell Proliferative
T-cell Proliferative Responses to PAP-derived Peptides Can Be Detected in Patients with Proliferative T-cell Responses Specific
for PAP. To determine whether the peptides chosen could represent PAP-specific Th epitopes, the peptides were used as stimulator antigens in proliferation assays in male subjects with and without PAPspecific T-cell responses. We have found previously (15) that some men with prostate cancer have detectable T-cell proliferative responses specific for PAP, and although these responses are generally low-level (SI < 4), the prevalence of responses is higher in patients with prostate cancer than in controls. Similar methods have been used previously (49, 50) in other systems to identify helper epitopes from large panels of overlapping peptides using PBMCs from antigenimmunized patients. Fig. 2 shows an example in which T cells obtained preoperatively from a 63-year-old male with clinically localized prostate cancer were found to proliferate in response to stimulation with PAP, with a SI of 3.3. In this subject, T-cell proliferation in response to individual peptide stimulation with a SI greater than 2.0 5162 was not detected; however, responses with 3 of 24 and 4 of 24 positive from the seven prostate cancer subjects with detectable T-cell rewells were detected to peptides p228-242 and pi99-213, respectively. This type of analysis was applied to PBMCs from 20 subjects, as shown in Fig. 3 . Thirteen of these subjects had no detectable immunity to PAP (eight of which had prostate cancer and five of which were male control blood donors without prostate cancer), and seven were patients with prostate cancer with detectable immunity to PAP. In Fig. 3A , few peptide-specific responses could be detected in PBMCs from the 13 subjects who had no detectable T-cell responses specific for PAP, both patients with prostate cancer and male control donors. In Fig. 35 , however, some level of peptide-specific T-cell immunity could be detected to each of the peptides using PBMCs sponses specific for PAP.
pl99-213 and p228-242 Represent Th Epitopes of PAP. We next wanted to determine whether any of the peptides constructed could represent naturally processed PAP-derived helper epitopes, capable of priming T-cell responses in vitro to respond to PAP protein. Given that the experiments were done irrespective of binding to specific MHC class n types, we chose to prioritize for study only those peptides identified above to which responses occurred in the majority of subjects with PAP-specific T-cell responses compared with subjects without PAP-specific T-cell responses. Consequently, four peptides were chosen, p81-95, pl99-213, p228-242, and p308-322, given that at least 4 of 7 of the PAP-specific PBMC specimens proliferated in response to these peptides (Fig. 3) . In addition, because our ultimate goal was to identify peptides that might be capable of eliciting Th responses to PAP in patients with prostate cancer, PBMCs from 12 patients with advanced stage prostate cancer and without PAPspecific proliferative responses (data not shown) and of presumably diverse MHC class II backgrounds were chosen for limited T-cell culture experiments. PBMCs from these 12 patients were stimulated in vitro with each of the four peptides (p81, pl99, p228, and p308). After three to five in vitro stimulations with peptide, T-cell cultures were assessed for proliferation in response to either the stimulating peptide or PAP protein. Fig. 4 shows an example of results from one individual patient. Before culture (Fig. 4A) , this patient did not have evidence of PAP-specific or peptide-specific T-cell proliferation. After four in vitro stimulations with either pl99-213 peptide (Fig. 45) or p308-322 peptide (Fig. 4Q , peptide-specific T-cell proliferation could be detected. No specific proliferation could be detected after culture with p81 -95 or p228-242 in this particular patient (data not shown). In addition, whereas no PAP-specific T-cell proliferation could be detected in the p308-322 culture (Fig. AC) , PAP-specific T-cell proliferation could be detected in PBMCs cultured with pl99-213 peptide (Fig. 45) . A summary of similar results for the 12 patients is shown in Table 2 . As demonstrated, peptide-specific lines could be generated to each of the peptides in at least 1 of the 12 patient samples. Of the 
peptide-specific lines, however, only pi99-and p228-specific lines also proliferated in response to PAP protein, suggesting that these two peptides represent naturally processed PAP-specific MHC class II epitopes.
DISCUSSION
Th cells are of central importance in the generation of immune responses (3). Animal models have underscored the necessity of tumor-specific Th cells directly or indirectly by recruiting other effector cells for maintenance of therapeutic antitumor immune responses (10, 51, 52). CTLs, in particular, have been shown to require CD4+ Th cells for long-term memory, survival, and cytolytic efficacy (7, 8) . In the current study, we used PBMCs from patients with detectable Th immunity to PAP to identify potential PAP-specific Th peptide epitopes. We report that epitopes can be identified by motif analysis and that peptides identified in this fashion could be used to prime PAP-specific Th responses in vitro. By this means, we identify The identification of Th epitopes has traditionally been done either by eluting peptides bound to specific MHC class II molecules or by screening panels of overlapping peptides derived from the antigen being studied. The first method, eluting and sequencing peptides bound to specific MHC class II molecules from antigen-presenting cells, has been used to identify MHC class II epitopes associated with insulin-dependent diabetes (S3, 54), multiple sclerosis, and rheumatoid arthritis (55) , as well as from the melanoma tumor antigens tyrosinase (12) and gplOO (13) . Obviously, elution of peptides from specific MHC class II molecules requires selection of specific MHC restriction elements for study. This method is also potentially cumbersome, identifying epitopes from multiple processed antigens and not specifically a single antigen under study (56) . Moreover, it is generally believed that MHC class II epitopes are less length-and sequence-constrained compared with MHC class I epitopes and, in fact, that specific Th epitopes may bind multiple MHC class II molecules (53, 56, 57) . Because we wanted to identify epitopes that might be common to many patients of diverse MHC backgrounds, we chose to screen peptides using PBMCs irrespective of specific MHC class II types. In that regard, studies identifying Th epitopes of the diphtheria toxin identified epitopes that were common to several patients of diverse MHC class II backgrounds (50) .
Other groups have identified Th epitopes by screening panels of overlapping peptides derived from the antigen being studied using PBMCs from immune individuals. Th epitopes from tetanus toxoid (48) and diphtheria toxin (50) , as well as the MAGE-3 melanoma tumor antigen (14) , have been identified by this method. In the case of tetanus and diphtheria toxins, panels of peptides of varying lengths were used, spanning the entire length of the proteins, as stimulator antigens in T-cell proliferation assays to determine which peptides stimulated proliferation using PBMCs from tetanus-immune individuals (48, 49) . The advantage to this type of approach is that the results are exhaustive, spanning the entire length of the immunogen, and have identified peptide epitopes common to most immune patients of presumably diverse MHC class II types. In addition, this method identified peptides of 14-16 amino acids in length as efficient in eliciting Th proliferation. We adopted a similar strategy to define Th epitopes from PAP, given that we had identified previously (15) that some patients with prostate cancer have detectable Th immune responses to PAP. A comprehensive study of overlapping peptides would have been less feasible in our system, however, given that Th responses to PAP were found previously to be rare among patients and are generally of low magnitude. Consequently, an exhaustive search of overlapping peptides would have necessitated extremely large numbers of PBMCs (>10 9 cells) to detect low-level responses. Therefore, we purposefully chose to bias our selection of peptides, using algorithms to identify potentially antigenic regions of the PAP protein of 15-18 amino acids in length. Although this method may certainly have missed potential epitopes, the fact that we identified two Th 5165 epitopes of 10 peptides studied demonstrates the feasibility and utility of this method.
In the current study, we identified peptides derived from PAP, Th proliferative responses to which were associated with responses to soluble PAP protein. In fact, responses to each of the peptides were found in at least one of the seven patients with previously identified Th responses to PAP. This suggests that all of these peptides could represent PAP Th epitopes presented by different MHC class II epitopes present in some individuals but not in others. We were particularly interested in identifying epitopes that might be capable of binding multiple MHC class II types and, therefore, be more "universal" as Th epitopes, similar to peptides identified for diphtheria toxin (50) . Consequently, we prioritized for study only those four peptides identified that stimulated T-cell proliferation in the majority of PBMC samples that also exhibited PAP protein-specific T-cell proliferation. By repetitive in vitro stimulation, peptide-specific T-cell lines could be generated from each of these four peptides from at least 1 of 12 PBMC specimens obtained from patients with prostate cancer who had no detectable preexisting peptide-specific or PAP-specific Th responses. Peptide-specific lines derived from two peptides, p 199-213 and p228-242, were also able to proliferate in response to PAP protein stimulation, suggesting that these represent MHC class II epitopes naturally presented after antigen processing.
The development of vaccines capable of eliciting prostate-specific immunity for the treatment of prostate cancer is an active area of research (20) . Clinical trials underway include cytokine-transfected whole cell vaccines (58), protein-based vaccines (21), viral-based vaccines (59, 60) , and dendritic cell vaccines pulsed with either MHC class I-restricted peptide epitopes (61) or proteins, including PAP (22, 62) . Immunization directly with MHC class I peptides represents another vaccination approach that has shown success in eliciting antigen-specific CD8+ T cells in human clinical trials, in some cases with the suggestion of clinical benefit (63) (64) (65) . Similar trials (16, (23) (24) (25) (26) (27) have been contemplated in prostate cancer, particularly because MHC class I epitopes have already been identified for PAP, prostate-specific antigen, and prostate-specific membrane antigen. Animal studies (19) have suggested the importance of CD8+ T-cell immunity for actual immune-mediated destruction of prostate tissue. Consequently, antigen-specific Th cells, and Thl cells in particular, may be particularly important for the effectiveness and maintenance of prostate-specific CTLs (9, 15, 66) . Data presented here represents the first report of PAP-specific Th epitopes and a demonstration that PAP-specific Th responses can be elicited in vitro after culture with these epitopes. Ongoing studies will evaluate whether peptide-specific lines exhibit a Thl-or Th2-type bias with respect to cytokine secretion. Given the importance of Th cells in effective antitumor immune responses, vaccine strategies, and MHC class I peptide-based vaccine strategies in particular, targeting this protein might be further enhanced by inclusion of these epitopes capable of inducing PAPspecific Th responses.
INTRODUCTION
Several cell populations are involved as effector cells in antitumor immune responses, including lymphocytes, natural killer cells, macrophages, and eosinophils. Cytotoxic T lymphocytes (CTL) have long been considered to be the primary effector cell population critical for effective antitumor immunity, given their ability to discriminate and lyse cells expressing tumor-associated antigenic peptides in the context of MHC class I molecules [1] [2] [3] . Rodent models of experimental autoimmune prostatitis have suggested that CTLs are critical for actual destruction of prostate tissue [4] [5] [6] . These findings have suggested that the induction of tumor-specific CTL .will likely be important for the immunological treatment of prostate cancer [7,81. Recent studies have demonstrated the central involvement of helper T cells (Th) in antitumor immunity [9] [10] [11] [12] . Th cells may participate by supporting the development of effective CTL [13] [14] [15] , by themselves lysing tumor cells independent of CD8 + CTL [16] , or potentially by recruiting other effector cells, including macrophages and eosinophils [9, 10, 17] . In general, Th cell responses tend to be polarized to either a Thl-like or Th2-like phenotype based on the patterns of cytokines secreted [18] . The Thl phenotype, typified by secretion of lymphotoxin, tumor necrosis factor a (TNFa) and interferon y (IFNy), has been more associated with cellular inflammatory immune responses with concurrent antigen-specific CTL, activated macrophages, and delayed-type hypersensitivity (DTH) reactions. This type of immune response has been demonstrated to be protective against the development of certain types of intracellular pathogens, in mediating various tissue destructive autoimmune states, and in eliciting antitumor responses [10, [19] [20] [21] . By contrast, the Th2 immune response, typified by secretion of the interleukins IL-4, IL-5, IL-6, IL-10, and IL-13, has been more associated with promoting humoral immune responses and the development of peripheral tolerance [19, [22] [23] [24] .
Studies in patients with metastatic prostate cancer have suggested that T cells nonspecifically stimulated by mitogenic stimuli tend to be Th2 biased, as compared with normal donors [25] [26] [27] . These types of findings have led investigators to speculate that an imbalance of Th subsets may lead to decreased immune surveillance and tumor escape in patients with cancer [28] . Others have suggested that impaired signal transduction in peripheral T cells in patients with prostate cancer may lead to decreased tumor surveillance [29] . In this report, we explored whether patients with prostate cancer have Th responses specific for two prostate cancer-associated antigens, prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP), by evaluating T cell proliferation in response to antigen stimulation. In addition, we determined whether Thl responses to these antigens could be detected in patients with prostate cancer, implying an immune environment capable of supporting antigen-specific CTL.
METHODS
Subject Populations
With informed consent, 70 ml blood were obtained from 80 patients with prostate cancer, as well as 20 male volunteer blood donors without histories of prostate disease, at the University of Washington Medical Center between 1997 and 1999. Peripheral blood mononuclear cells (PBMC) were prepared by Ficoll-Paque centrifugation (Pharmacia AB, Uppsala, Sweden) and cryopreserved in liquid nitrogen. PBMC were classified according to the patients disease stage and treatment status into two general groups, each with 40 patients. The first group consisted of patients with clinically localized prostate cancer, samples collected either before treatment or at a variety of times following primary therapy. The second group consisted of patients with stage D prostate cancer, either responsive or unresponsive to androgen ablative therapy.
Detection of Antigen-Specific T Cell Immunity by 3 H-Thymidine Incorporation Assay
The results are reported as a stimulation index (S.I.), defined as the mean of experimental wells divided by the mean of the control wells (no antigen). For all of the assays performed, the same three lots of purified protein were used to ensure reproducibility of results. All positive results were confirmed with two different lots of protein, with the S.I. reported as the mean of the two assays. A result was considered significant if the S.I. was greater than the mean +3 SD of the S.I. determined for the control population (n = 20). All patients had proliferative responses to PHA, defined as an S.I. > 3.
Characterization of theTCell Response by Cytokine Release
T cells proliferating in response to antigen stimulation were characterized with respect to phenotype, Thl or Th2, by cytokine release quantified by enzymelinked immunosorbent assay (ELISA). Short-term T cell cultures were established from PBMC as above with 2 ug/ml PSA, 2 ug/ml PAP> 2.5 ug/ml PHA, or no antigen for 5 days at 37°C/5% CQ,-Murine monoclonal antibodies specific for either human IFNy (Genzyme, Cambridge, MA) or human IL-5 (Pharmingen, San Diego, CA) were diluted to 2.5 ug/ml in 50 mM sodium carbonate buffer (pH 9.6) and adsorbed to wells of Immulon-4 polystyrene plates (Dynex Technologies Inc., Chantilly, VA) overnight at 4°C. Wells were then blocked with PBS/1% BSA/0.05% Tween-20 for 3 hr at room temperature, and then washed with PBS/0.1% Tween-20. Supernatants from the shortterm cultures were then pooled, and 50 ul were added to replicate experimental wells. A standard curve of either purified IFNy (RDD (0.24-4,000 pg/ml) or IL-5 (Pharmingen, San Diego, CA) (0.24-4,000 pg/ml) was included on each ELISA each plate. Plates were then incubated overnight at 4°C, washed, then incubated for 2 hr at room temperature with a biotinylated secondary antibody (anti-IFNy, Pharmingen; anti-IL5, Pharmingen) diluted to 1 ug/ml. After washing, the plates were incubated for 1 hr at room temperature with peroxidase-conjugated streptavidin (Amersham, Arlington Heights, IL) diluted 1:3,000, washed again, and developed with TMB peroxidase substrate (Kierkegard and Perry Laboratories, Gaithersburg, MD). Reactions were stopped with addition of 0.5 N HC1 and the optical densities (ODs) of experimental wells were read at 450 nm. Concentrations of IFNy or IL-5 were calculated by comparison of the obtained OD with the standard curve. Antigen-specific concentrations were determined by subtracting the background concentrations determined from the "no-antigen" control .wells. Data reported show the mean and standard deviation of 4-well replicates for each culture sample.
For IFNy the limit of detection was 8 pg/ml, and for IL-5 the limit of detection was 2 pg/ml.
Statistical Analysis
Comparison of study populations was performed using a x 2 test/ with P < 0.05 considered statistically significant. T cell proliferative responses specific for PSA and PAP were detected in patients with prostate cancer. As an example, PBMC obtained from a 51-year-old male with stage Dl prostate cancer were stimulated in vitro with varying concentrations of PAP, PSA, ovalbumin or PHA (Fig. 1) . In this patient, significant T cell proliferation was detected in response to PAP (S.I. 3.4 at 2 ug/ml PAP concentration) and PSA (S.I. 3.9 at 2 ug/ml PSA concentration) stimulation. Response to PAP was found to be dose-responsive in several patients (data not shown), with significant differences detected at a concentration of 2 ug/ml. For this reason, subsequent analysis was conducted at a standardized protein concentration of 2 ug/ml.
RESULTS
Patients
Patients With Metastatic Prostate Cancer Can Have
TCell Proliferative Responses Specific for PSA Eighty patients with various stages of prostate cancer and 20 controls were evaluated for T cell proliferation in response to PSA stimulation. As shown in Figure 2 , patients with prostate cancer could be detected with significant recall responses to PSA, particularly patients with metastatic disease. The mean S.I. of the control population was found to be 0.9 ±0.4. Five patients (12%) with metastatic prostate cancer were found to have significant T cell responses, defined as an S.I. greater than the mean + 3 SD of the S.I. of the control population. This was notably different from the population of patients with limited stage disease, none of whom (0/40) was found to have an S.I. greater than 3 SD from the mean of the control population (P = 0.02).
Patients With Prostate Cancer Can Have TCell Proliferative Responses Specific for PAP, Irrespective of the Stage of Disease
The same patients and controls were evaluated for T cell proliferation in response to PAP stimulation, as shown in Figure 3 . Unlike PSA, no differences were the prostate, we explored whether T cell responses specific for these proteins could be detected in patients with prostate cancer. We then evaluated whether IFNy-secreting, Thl-type cells could be detected, suggesting an immune environment capable of supporting antigen-specific CTL.
We find that preexisting T cell responses to PSA and PAP can be identified in a minority of patients with prostate cancer. The prevalence and magnitude of detectable responses to both antigens were low. This is perhaps not surprising, given that these are autologous proteins, and therefore same degree of immune tolerance to these proteins is expected. Unlike infectious disease models, in which antigens are foreign proteins and therefore usually elicit robust immune responses, identified tumor antigens are typically "self" or "altered-self' proteins [34, 35] . The presence of even a low-level immune response in some patients with antigen-expressing tumors, however, suggests that immune tolerance to the antigen can be circumvented in vivo. Results from a clinical vaccine study, in which patients with prostate cancer were immunized with PSA protein, found that two of ten patients prior to vaccination had a detectable CD4 + (typically Th) cell response specific for PSA. These findings are certainly consistent with our prevalence results.
In the case of PSA, responses were detected in patients with metastatic disease but not early stage disease. T cell responses specific for PAP were found in patients irrespective of disease stage. Alexander and colleagues have recently reported that proliferative T cell responses to PSA, but not PAP, could be detected in 5/14 patients with chronic prostatitis [36] . They suggest that the presence of responses to PSA in this population implies that PSA may be a natural target of an autoimmune response, and therefore a reasonable target for immune-based treatments of prostate cancer [36] . Our results represent the first report detailing naturally occurring T cell responses specific for PSA and PAP in a large population of patients with prostate cancer. Of note, there was no history of prostatitis in the five patients identified in the current study with T cell responses specific for PSA, although a detailed history of prostatitis symptoms was not obtained from all study subjects. A priori, it is not clear why the incidence of T cell responses to PAP would be different from PSA, or why the incidence of responses would be different in distinct patient populations. Both proteins are essentially tissue-specific and secreted proteins expressed in normal and malignant prostate cells. It is possible that differences in the incidence of T cell responses is due to differences in the immunogenicity of these proteins as has been suggested [36] . We have previously reported that patients with metastatic prostate cancer, but generally not patients with earlier stage disease, can have detectable antibody responses to PSA [37] ! Those antibody responses were all of the IgG type (unpublished observations), further implicating the presence of PSA-specific Th cells involved in immunoglobulin class switch.
A small number of patients with prostate cancer could be identified with a type 1 pattern of T cell cytokine secretion in response to PSA or PAP stimulation. Previous studies evaluating cellular immune responses in patients with prostate cancer have suggested that patients have a global Th2 bias [25] [26] [27] . Elsasser-Beile and colleagues have reported that lymphocyte cultures from patients with prostate cancer stimulated by mitogens produce less IFNy when compared to normal controls [25] and that this tends to be most pronounced in patients with higher tumor burdens [26] . These studies, however, were conducted to evaluate nonspecific mitogenic stimulation, and did not evaluate antigen-specific responses. Our findings demonstrate that patients with prostate cancer can, in fact, have Thl-type proliferative T cell responses to autologous prostate-specific proteins. While this does not exclude the possibility that Th2 responses to these antigens can exist, it would suggest that a tumor antigen-specific Th2 bias does not necessarily occur in patients with prostate cancer.
Clinical vaccine trials for patients with prostate cancer targeting PSA and PAP are under investigation by several groups [30, [38] [39] [40] [41] . Vaccine strategies, including dendritic-cell-based strategies, known to elicit Thl responses and CTL responses, -are of particular interest, as such strategies have been suggested to have clinical benefit [41, 42] . The results reported here demonstrate that Thl responses to prostate cancer-associated proteins can exist in vivo, and therefore may potentially be either elicited or augmented through antigen-specific yaccine strategies capable of producing this type of immunity. Results from ongoing and future prostate cancer vaccine trials should determine whether these strategies are indeed capable of eliciting a prostate-destructive CTL response, and whether that response is associated with a therapeutic response.
